

# Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Consultation Procedure under Section 35a paragraph 3b SGB V:

Iptacopan (paroxysmal nocturnal haemoglobinuria);  
requirement of routine practice data collection and  
evaluations

of 20 March 2025

At its session on 20 March 2025, the Federal Joint Committee (G-BA) decided the following:

- I. The consultation procedure on the requirement of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient Iptacopan for the treatment of  
"Therapy-naive adults with paroxysmal nocturnal haemoglobinuria who have haemolytic anaemia"  
is suspended.
- II. The resolution will enter into force on the day of its publication on the website of the G-BA on 20 March 2025.

The justification to this resolution will be published on the website of the G-BA at [www.g-ba.de](http://www.g-ba.de).

Berlin, 20 March 2025

Federal Joint Committee (G-BA)  
in accordance with Section 91 SGB V  
The Chair

Prof. Hecken